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Abstract
Background and Purpose: Extracellular adenosine triphosphate (ATP) regulates inflammatory cells by activation of the P2X7
receptor. We hypothesized that polymorphisms in P2RX7 influence the risk of ischemic heart disease (IHD), ischemic stroke
(IS) and cardiovascular risk factors and tested this hypothesis using genetic association studies.
Methods: Two loss-of-function SNPs in P2RX7 were genotyped in 1244 IHD cases and 2488 controls as well as 5969
individuals with cardiovascular risk factors. Eleven SNPs in a 250 kb region on chromosome 12 spanning P2RX7 as well as
neighboring genes OASL, P2RX4 and CAMKK2 were genotyped in 4138 individuals with IS and 2528 controls. Association was
examined using linear and logistic regression models with an additive genetic model.
Results: The common loss-of-function variant rs3751143 was significantly associated with a decreased risk of IHD in smokers
(P=0.03) as well as decreased risk of IS (OR 0.89; 95% CI=0.81–0.97; P=0.012). In addition, an intronic SNP in CAMKK2,
rs2686342, were associated with a decreased risk of IS (OR 0.89; 95% CI=0.82–0.97; P=0.011). In subgroup analyses, both
SNPs were associated with decreased risk of IS in individuals with hypertension (P=0.045 and 0.015, respectively).
Conclusions: A common loss-of-function missense variant in the gene encoding the P2X7 receptor is associated with
reduced risk of IS and with IHD in smokers. These findings might implicate a role of purinergic signaling in atherogenesis or
atherothrombosis.
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Introduction
Ischemic heart disease (IHD) and ischemic stroke (IS) are
leading causes of death and disability in developed countries and
have rapidly increasing disease rates in developing countries. A
substantial proportion of cases are considered to be caused by
erosion or rupture of an atherosclerotic plaque followed by
thrombus formation but many risk factors, both environmental
and genetic, contribute to the pathogenesis [1].
Extracellular purines and their purinergic receptors are
important cardiovascular regulators and could influence the risk
of cardiovascular disease by several different mechanisms includ-
ing regulation of platelet aggregation, inflammation, vascular and
cardiac function [2,3]. So far, ADP receptor P2Y12 antagonists
have achieved clinical utility in prevention of IHD and IS, [4] but
several other P2 receptors constitute potential drug targets. One of
the most interesting candidates is the P2X7 receptor. The P2X7
receptor induces mitosis and prevents apoptosis of T-lymphocytes
and is an important activator of macrophages [5,6]. Furthermore,
it regulates the release of cytokines including interleukin-1b [7],
tumour necrosis factor [8] and L-selectin, an adhesion molecule
important for lymphocyte binding to endothelium [9]. All of these
effects have been shown to be involved in atherogenesis.
The P2X7 receptor gene (P2RX7) is highly polymorphic. At least
11 non-synonymous polymorphisms have been identified in the
coding region [10] and several of these results in altered function
of the receptor. We hypothesized a role of the P2X7 receptor in
cardiovascular disease and tested the hypothesis using a genetic
association study. Findings from genetic association studies with
small sample sizes frequently suffer from non-reproducibility [11].
We therefore used a large sample, the population-based Malmo ¨
Diet and Cancer study (MDCS, n=28 449) which includes two
subsamples; nested case-control samples of individuals who
developed IHD (1244 cases and 2488 controls) during follow-up
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37491and a randomly selected subsample, the cardiovascular cohort
(MDC-CC, n=5969) [12] in which cardiovascular biomarkers
and ultrasound measures of carotid intima-media thickness (IMT)
were measured. In a secondary analysis we wanted to confirm the
cardiovascular effect in a stroke sample. Association with IS was
examined using three case-control studies of ischemic stroke, the
MDCS (888 cases and 893 controls), the Lund Stroke Register
(LSR, 2397 cases and 960 controls) and the Sahlgrenska Academy
Study on Ischemic Stroke (SAHLSIS, 844 cases and 688 controls)
from Southwestern Sweden.
Methods
Study samples
Descriptions of all samples are shown in Table 1. Sample
collection, definitions and characteristics for MDCS, LSR and
SAHLSIS have been described previously [12–15]. Briefly,
MDCS is a population-based, prospective cohort study, which
included 28 449 randomly selected men (born between 1926–
1945) and women (born between 1923–1950) from the city of
Malmo ¨ at baseline examinations between 1991 and 1996. Blood
samples and information on risk factors were ascertained.
Individuals who developed IHD or IS during follow-up were
included in the present study together with two age and sex
matched controls per case for IHD and one control per case for IS.
Individuals with previous IHD or IS at baseline were excluded. A
randomly selected subcohort of the MDCS, the cardiovascular
cohort (MDC-CC, n=6103), underwent B-mode ultrasound
measurement of carotid intima-media thickness (IMT) and
occurrence of plaques and sampling of peripheral venous blood
on which plasma biomarkers including high-sensitivity C-reactive
protein (hsCRP) and blood lipids were measured. From this
sample, DNA was available for 5969 individuals. LSR is a
prospective register study which consecutively includes all patients
with a first case of ischemic or hemorrhagic stroke in the
catchment area of Lund University Hospital. Blood samples and
information on risk factors were collected from patients with
ischemic stroke between 2001 and 2006. Control subjects were
randomly selected from the same region matched by age and sex
to LSR cases using the Swedish Population Register. SAHLSIS is
a case-control study comprising patients with first-ever or
recurrent acute IS before the age of 70 years who were enrolled
between 1998 and 2008 at four stroke units in Western Sweden.
Controls without cardiovascular disease were randomly selected
from the same geographical region as the patients.
Diabetes mellitus was defined as a physician’s diagnosis of
diabetes or use of antidiabetic medications in all samples except
MDC-CC where fasting blood glucose was measured and values
$6.1 mmol/l were also considered as diabetes. Blood pressure was
measured using a mercury-column sphygmomanometer after
10 minutes of rest in the supine position in MDCS and SAHLSIS
and ascertained from patient records in LSR. Hypertension was
defined as blood pressure $160/90. Current smoking was
ascertained from a questionnaire. Informed consent was obtained
from all participants and the study was approved either by the
Ethics Committee of the University of Gothenburg or by the
Ethics Committee of Lund University.
Clinical outcomes
Cardiovascular events were identified in MDCS by linkage of
Swedish personal identification numbers to the Swedish Hospital
Discharge Register and the Swedish Cause of Death Register for
IHD and to the Stroke Register of Malmo ¨ (STROMA) [16] for IS,
including events until December 31, 2003. IHD was defined as
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37491codes 410 and I21 in the International Classification of Diseases 8
th,9
th
and 10
th Revisions, respectively. Ischemic stroke was ascertained
in accordance with WHO criteria [17] in all samples as previously
described [13,15,18].
Measurement of carotid IMT and hsCRP
Common carotid IMT and IMT in the carotid bifurcation was
measured using B-mode ultrasonography (Acuson 128 CT system)
according to a standardized protocol by trained, certified
sonographists as previously described [19]. hsCRP was measured
using a high-sensitivity assay (Tina-quant, Roche Diagnostics,
Basel, Switzerland) on an ADVIA 1650 Chemistry System (Bayer
Healthcare, Leverkusen, Germany) with fasting plasma samples.
Genotyping and quality control of SNPs
Two loss-of-function SNPs in P2RX7, rs3751143 and rs2230911
were genotyped in the MDC-IHD sample. In the larger stroke
sample, a total of 11 SNPs in a 250 kb region spanning P2RX7 as
well as neighboring genes OASL, CAMKK2 and P2RX4 were
genotyped. A schematic map of the genomic region is shown in
Figure 1. SNPs were chosen based on reported functional effects or
disease associations. For LSR samples, DNA-isolation and
genotyping were performed at the SWEGENE Resource Center
for Profiling Polygenic Disease, later to become the Region Ska ˚ne
Competence Center (RSKC) at Malmo ¨ University Hospital,
Malmo ¨, Sweden. Genotyping was performed on a MALDI-TOF
mass spectrometer (SEQUENOM Mass Array) using Sequenom
reagents and protocols with 10 ng DNA template. The same set of
reagents was used in all samples for stroke. Automatic allele calls
by SEQUENOM software were validated by manual evaluation.
MDC-CC samples were genotyped using a TaqMan ABI 7900
HT according to the manufacturer’s protocol with SNP genotyp-
ing assays C_15853705_20 and C_27495274_10 from Applied
Biosystems. All laboratory analyses were blinded.
Statistical analysis
Assuming an additive inheritance model, we used logistic
regression analysis to test for difference of minor allele dosage
between cases (IHD or IS) and controls and to estimate odds ratios
for qualitative traits. SAHLSIS, LSR and MDCS were pooled for
analysis of IS. For quantitative traits (i.e. intima media thickness
and hsCRP), we used linear regression models with dosage of
minor alleles as independent variable. hsCRP was positively
skewed and was log-transformed before analysis. Adjustments
were made for age, sex and cardiovascular risk factors (hyperten-
sion, diabetes and current smoking). Subgroup analyses were
performed in individuals affected by known risk factors of
cardiovascular disease, i.e. diabetes, hypertension and current
smoking as well as in individuals with early disease onset (,60
years). P-values ,0.05 were considered significant. All statistical
analyses were performed in SPSS (SPSS v16, SPSS Inc., Chicago,
Illinois). Hardy-Weinberg equilibrium was examined in Haplo-
view 4.2 in each sample. Analysis of correlation between SNPs as
well as calculation and visualization of linkage disequilibrium (LD)
was done in Haploview 4.2 using the LSR sample. Haplotype
blocks were defined using confidence interval bounds as described
previously [20].
Results
Allele frequencies and quality control
Information on all SNPs included in the study is summarized in
Table 2 and their positions in the genome are shown in Figure 1.
All SNPs were successfully genotyped with ,5% missing
genotypes in all samples and with the exception of rs3817190
(P=0.029) did not differ significantly from Hardy-Weinberg
Equilibrium for cases or controls. Minor allele frequencies
(MAF) were similar across samples and comparable to previous
reports in the literature [10] and the HapMap project. Genotype
distributions are summarized in Table S1.
Genotypic association with ischemic heart disease
In the first stage of the investigation, two loss-of-function SNPs
in P2RX7, rs3751143 and rs2230911 were genotyped in the
MDC-IHD sample. Neither of the SNPs were significantly
associated with IHD (p.0.05). In secondary analyses, the minor
allele of rs3751143 was protective of IHD in smokers (OR=0.77;
95% CI=0.61–0.97; P=0.03, n=1091) but not in non-smokers
(OR=1.05; 95% CI=0.90–1.23; P=0.56, n=2638). The asso-
ciation improved slightly after adjustment for age and sex
(OR=0.76; 95% CI=0.60–0.96; P=0.021). In smokers, the risk
of IHD was lower in homozygotes for the minor allele (n=9 cases
and 29 controls) than in homozygotes for the major allele (n=306
cases and 430 controls) with an odds ratio of 0.44 (95% CI=0.20–
0.93; p=0.03). The risk for heterozygotes with current smoking
Figure 1. Schematic map of the genomic region containing
OASL, P2RX7, P2RX4 and CAMKK2. A) Filled boxes represent genes.
Arrows indicate transcriptional direction. B) Filled boxes indicate exonic
regions. The position of each SNP included in the study is indicated by
vertical arrows.
doi:10.1371/journal.pone.0037491.g001
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from homozygotes for the minor allele, C (OR=0.84; 95%
CI=0.63–1.11; p=0.22).
Intima-media thickness and hsCRP
Neither of the SNPs analyzed in MDC-CC were significantly
associated with common or internal carotid IMT, hsCRP, blood
pressure, blood lipids, body-mass index or diabetes (p.0.05).
Genotypic association with ischemic stroke
To confirm the cardiovascular effect of rs3751143 and to
elucidate whether a correlated SNP might explain the association
in MDC-IHD, a total of 11 SNPs were genotyped in the three
stroke samples. In addition to the two loss-of-function SNPs in
P2RX7 genotyped in MDC-IHD, nine SNPs in P2RX7 as well as
neighboring genes OASL, CAMKK2 and P2RX4 were analyzed.
The additional SNPs were chosen based on functional effects or
relevant disease associations described in the literature [10,21–29].
IS was significantly associated with rs3751143 (P2RX7c.
1488A.C, p. Glu496Ala) and rs2686342 (CAMKK2c.
1452+1221A.T). The minor alleles of both SNPs were associated
with a decreased risk of developing IS with an OR of 0.89 (95%
CI=0.81–0.97, P=0.012) for rs3751143 and 0.89 (95%
CI=0.82–0.97, P=0.011) for rs2686342. The associations were
not affected substantially by adjustment for cardiovascular risk
factors (OR=0.87; 95% CI=0.79–0.97; P=0.008 and
OR=0.88; 95% CI=0.80–0.97; P=0.009, respectively). Odds
ratios for rs3751143 in each individual sample were 0.88 (95%
CI=0.76–1.02) in LSR, 0.84 (95% CI=0.70–1.01) in MDC-IS
and 0.97 (95% CI=0.80–1.17) in SAHLSIS after adjustments for
age and sex. Odds ratios for rs2686342 in each sample were 0.91
(95% CI=0.79–1.04) in LSR, 0.88 (95% CI=0.75–1.04) in
MDC-IS and 0.94 (95% CI=0.78–1.14) in SAHLSIS after
adjustments for age and sex. Adjustment for cardiovascular risk
factors did not substantially affect the odds ratios or confidence
intervals in either study (Data not shown). In subgroup analyses,
both rs3751143 and rs2686342 minor alleles were significantly
associated with decreased IS risk in individuals with hypertension
(n=3889; OR=0.88; 95% CI=0.77–1.00; P=0.045 and
OR=0.86; 95% CI=0.76–0.97; P=0.015, respectively) but not
in non-hypertensive individuals (n=2703; OR=0.88; 95%
CI=0.76–1.02; P=0.06 and OR=0.92; 95% CI=0.81–1.06;
P=0.26, respectively). The minor allele of rs2686342 was also
associated with a more pronounced risk reduction in individuals
with diabetes (n=940; OR=0.70; 95% CI=0.51–0.97;
P=0.030) than without diabetes (n=5531; OR=0.90; 95%
CI=0.82–0.99; P=0.034). Neither SNP was significantly associ-
ated with IS in patients with early disease onset or current smoking
even though effect estimates were similar but with wider
confidence intervals.
Pair-wise correlations between each of the two SNPs signifi-
cantly associated with IS and the rest of the SNPs in the study were
analyzed in the LSR sample (Table S2). rs3751143 and rs2686342
were more strongly correlated with each other (r
2=0.24) than with
any other SNP included in the study.
Testing for LD
We examined the patterns of LD between alleles at polymorphic
loci using all SNPs in the LSR sample (Figure 2). We detected two
independent haplotype blocks within the investigated region. The
first block is approximately 7 kb long and spans four SNPs in exon
11 and 13 of P2RX7. The second block is 18,5 kb in size and spans
two SNPs, one in exon 7 of P2RX4 and one in intron 3 of
CAMKK2. The SNPs that were significantly associated with IS
(rs3751143 and rs2686342) were located on separate blocks.
Discussion
In this large genetic association study we detected that a loss of
function variant of the pro-inflammatory ATP receptor P2X7 was
associated with reduced risk of ischemic heart disease in the
subgroup of smokers. Together with pre-clinical data this indicates
a possible role in atherosclerotic disease. We therefore examined
the variant and neighbouring SNPs in a large case-control stroke
population. Here we found that the variant was associated with
reduced risk of ischemic stroke.
We found that the minor allele of rs3751143 confers a reduced
risk of ischemic heart disease in smokers. This association
constitutes a subgroup analysis and hence should be considered
with caution. However, known loss of function in the genetic
variant [29] and the corresponding effect detected in IS makes our
finding more likely to constitute a ‘true’ association. Increased
Table 2. Description of SNPs included in the study.
SNP ID
Position, chr
12* Position, gene Function
%
Genotyped
Alleles
(major:minor) MAF
HWE
Controls (P) Samples genotyped
rs7965349 119956314 OASL. Intron 1 Intronic 99.5 G:A 0.20 0.44 SAHLSIS, LSR, MDC-IS
rs591874 120055848 P2RX7. Intron 1 Intronic 98.5 A:C 0.26 0.89 SAHLSIS, LSR, MDC-IS
rs17525809 120077072 P2RX7. Exon 2 Val76Ala 99.8 T:C 0.06 0.52 SAHLSIS, LSR, MDC-IS
rs208294 120084636 P2RX7. Exon 5 Tyr155His 99.5 C:T 0.44 0.90 SAHLSIS, LSR, MDC-IS
rs1718119 120099486 P2RX7. Exon 11 Ala348Thr 98.6 G:A 0.39 0.38 SAHLSIS, LSR, MDC-IS
rs3751143 120106687 P2RX7. Exon 13 Glu496Ala 99.8 A:C 0.16 0.34 SAHLSIS, LSR, MDC-IS, MDC-IHD
rs25644 120151029 P2RX4. Exon 7 Gly242Ser 98.6 A:G 0.12 0.19 SAHLSIS, LSR, MDC-IS,
rs2686342 120169571 CAMKK2. Intron 15 Intronic 98.3 T:A 0.20 0.81 SAHLSIS, LSR, MDC-IS,
rs3817190 120196460 CAMKK2. Exon 4 Ser85Thr 98.4 A:T 0.39 0.03 SAHLSIS, LSR, MDC-IS,
rs2230911 120099514 P2RX7. Exon 11 Thr357Ser 95.4 A:G 0.17 0.40 LSR, MDC-IHD
rs2230912 120106579 P2RX7. Exon 13 Arg460Glu 95.7 C:G 0.09 1 LSR
*Reference sequence NT_009775.16.
MAF:minor allele frequency, HWE: Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0037491.t002
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and may be associated both to an increased atherosclerotic burden
and to chronic inflammation, often manifesting as chronic
obstructive pulmonary disease (COPD). It is therefore conceivable
that an anti-inflammatory polymorphism might be of greater
benefit in smokers.
When examined in a large stroke population we could confirm
the cardiovascular effect of rs3751143. The minor alleles of
rs3751143, as well as of a SNP in neighboring gene CAMMK2,
rs2686342, were associated with a decreased risk of ischemic
stroke. rs3751143 is located in exon 13 of P2XR7 and is
particularly interesting since it confers a total loss of function of
the P2X7 receptor [29] (Glu496Ala). It has been associated with a
reduced clearance of M. tuberculosis by macrophages, increased
susceptibility to extra pulmonary tuberculosis and decreased
efficiency in killing intracellular Toxoplasma gondii [10,21,28].
Furthermore, a recent study showed that P2X7 receptor deficient
mice were protected from thrombosis in vivo [30]. rs2686342 is
located in intron 8 of CAMKK2 and little is known about its
functional effects. However, CAMKK2-deficient mice have been
shown to be protected against inflammation [31]. LD analysis
showed that the two SNPs were located on separate haplotype
blocks and linkage is therefore unlikely.
For the association study of ischemic stroke we used three
samples to increase our sample size. This sample size should allow
adequate statistical power to detect a modest risk estimate, based
on previous power analyses [32]. All samples were from
southwestern Sweden and have a uniform population history. It
is therefore unlikely that population stratification had a significant
impact on our findings as discussed previously [14]. The effect of
P2X7R Ala496 (rs3751143) in the SAHLSIS sample differed
somewhat from that in LSR and MDC but the confidence interval
overlaps with the effects in the other samples. The observations of
similar effects for Ala496 (rs3751143) in all stroke samples
separately with improved association with pooling and the
significant association in subgroups at high risk makes the
association more likely to be true.
Atherosclerosis is now considered an inflammatory disease in
which the macrophage is recruited to the cholesterol rich plaque
and activated by oxidized LDL [1]. The ATP-mediated activation
of the P2X7 receptor has been shown to be important for
macrophage activation. Our results suggest that loss of receptor
function is also associated with lower risk of cardiovascular disease.
If our findings can be replicated in additional samples and the
mechanism verified in functional analyses, this could motivate
inhibitors of P2X7 as the second antipurinergic treatment to reach
clinical trials for cardiovascular disease.
Supporting Information
Table S1 Genotype distributions of SNPs analyzed in
the stroke samples and in the ischemic heart disease
sample. A. Genotype distributions of SNPs analyzed in the
stroke samples. B. Genotype distributions of SNPs analyzed in the
ischemic heart disease sample.
(DOCX)
Table S2 Pair-wise correlations of rs3751143 and
rs2686342 and the other SNPs in the LSR sample. A.
Pair-wise correlations of rs3751143 and the other SNPs in the
LSR sample. B. Pair-wise correlations of rs2686342 and the other
SNPs in the LSR sample.
(DOCX)
Figure 2. Patterns of linkage disequilibrium within P2RX7, OASL, CAMKK2 and P2RX4. Shown are r
2-values between polymorphic loci in the
LSR sample. SNPs lying within blocks are depicted in bold type. Dark grey background: strong linkage; light grey background: uninformative; white
background: recombination.
doi:10.1371/journal.pone.0037491.g002
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